Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor

NCT01484873 · Completed

Last updated 2026-05-28

This clinical trial is testing a weight loss intervention in adults with obesity caused by craniopharyngioma or another brain tumor.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 10 people

Who can join Ages 18–40 · all sexes

Timeline Started 2012-06 · est. completion 2015-03

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT01484873 ↗

Description as written by the study sponsor.

The purpose of this study is to determine whether exenatide can cause weight loss in patients with a history of craniopharyngioma or other brain lesion.

Treatments tested

Exenatide also known as Byetta Drug

Treatment with exenatide 5 mcg twice daily for 4 weeks, then 10 mcg twice daily for 46 weeks.

Main thing measured	Body Weight (kg)
Sponsor	Vanderbilt University Medical Center
Conditions studied	Obesity, Overweight, Craniopharyngioma
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01484873 ↗